Are you Dr. Regev?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 18 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
720 Eskenazi Ave
Indianapolis, IN 46202Phone+1 317-880-8329Fax+1 305-243-8470- Is this information wrong?
Summary
- Dr. Arie Regev, MD is a gastroenterologist in Indianapolis, Indiana. He is currently licensed to practice medicine in Indiana and Florida.
Education & Training
- The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1988
Certifications & Licensure
- IN State Medical License 2007 - 2023
- FL State Medical License 2001 - 2007
Publications & Presentations
PubMed
- Nomenclature, Diagnosis and Management of Drug-induced Autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.Raúl J Andrade, Guruprasad P Aithal, Ynto S de Boer, Rodrigo Liberal, Alexander Gerbes, Arie Regev, Benedetta Terziroli Beretta-Piccoli, Christoph Schramm, David E Kle...> ;Journal of Hepatology. 2023 May 8
- Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver Chemistry.Enaksha Wickremsinhe, Antoniu Fantana, Erwin Berthier, Brook A Quist, Diego Lopez de Castilla, Charles Fix, Kahlil Chan, Jing Shi, Michael G Walker, Jennifer F Kherani...> ;The Journal of Applied Laboratory Medicine. 2023 May 4
- 6 citationsRedefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.Yasser Fouad, Melissa Palmer, Minjun Chen, Arie Regev, Rajarshi Banerjee, Rob Myers, Robert Riccio, Richard Torstenson, Ramy Younes, Puneet S Arora, Henrik Landgren, M...> ;Journal of Clinical and Translational Hepatology. 2022 Apr 28
- Join now to see all
Press Mentions
- Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic SteatohepatitisFebruary 14th, 2019
- Consensus: Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Patients with Nonalcoholic SteatohepatitisFebruary 13th, 2020